Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio Leads Strong Week for BCW Index

Shares in Harvard Bioscience climbed 19 percent for the five-day trading period ended Tuesday, leading all gainers in the BCW Index. The company is in the midst of seeking a buyer for its capital equipment business. The only other firm to eclipse 5 percent growth for the tracking period was Invitrogen, whose shares rose 5.3 percent. Stratagene led decliners with a 2.8 percent drop.

Overall, the Index rose 2.9 percent for the week, beating out the Dow Jones Industrial Average, which gained 1.5 percent. The Index did not perform as well as the Nasdaq, which closed up 3.4 percent for the week, or the Nasdaq Biotech Index, which climbed 3.9 percent.

BioCommerce Week Index of Diversified Molecular Biology Tool Companies
Company
Ticker
Current Price
(Jan 10, 2006)
Last Price
(Jan. 3, 2006)
% change
Agilent
A
35
33.5
4.48
Applied Biosystems
ABI
27.91
26.88
3.83
Beckman
BEC
58.36
56.97
2.44
Bio-Rad
BIO
67.27
65.45
2.78
Bruker
BRKR
4.93
4.94
-0.20
Fisher Scientific
FSH
65.78
62.2
5.76
GE
GE
35.19
35.37
-0.51
Harvard Bio
HBIO
5.63
4.73
19.03
Invitrogen
IVGN
69.82
66.34
5.25
Molecular Devices
MDCC
29.37
28.76
2.12
PerkinElmer
PKI
23.69
23.99
-1.25
Qiagen
QGEN
12.43
12.04
3.24
Sigma
SIAL
63.95
63.51
0.69
Stratagene
STGN
10
10.29
-2.82
Thermo
TMO
31.16
30.28
2.91
Waters
WAT
38.96
38.1
2.26
BCW Index Average
36.22
35.21
2.86
The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.